Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Zydus can launch ulcer...

    Zydus can launch ulcer drug in US, patent litigation settled

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2016-12-05T13:16:29+05:30  |  Updated On 5 Dec 2016 1:16 PM IST
    Zydus can launch ulcer drug in US, patent litigation settled

    New Delhi : Zydus Cadila, an innovation-driven global pharmaceutical company, announced that the patent litigation relating to Allergan's DELZICOL (mesalamine) has been settled. As a result of the settlement, and if approved by FDA, its US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of DELZICOL in the Unite States beginning of March 1, 2020, or earlier under certain circumstances.


    Stock View:


    Cadila Healthcare Ltd ended at Rs 395.25, down by Rs 4.35 or 1.09% from its previous closing of Rs 399.6 on the BSE.


    The scrip opened at Rs 400 and touched a high and low of Rs 401.05 and Rs 391.95 respectively. A total of 442882(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 40463.43 crore.


    The BSE group 'A' stock of face value Rs 1 touched a 52 week high of Rs 429.45 on 01-Nov-2016 and a 52 week low of Rs 295.5 on 18-Jan-2016. Last one week high and low of the scrip stood at Rs 414.6 and Rs 391.95 respectively.


    The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 17.25 % and 7.96 % respectively.


    The stock traded above its 50 DMA.

    AllerganCadila HealthcareDELZICOLpatent litigationulcer drugzydus
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok